EMA Application withdrawn: Fanskya (mozafancogene autotemcel) — Rocket Pharmaceuticals B.V.

View source ↗

Summary

The European Medicines Agency has withdrawn the marketing authorization application for Fanskya (mozafancogene autotemcel) intended to treat Fanconi anemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fanconi Anemia

Drugs mentioned

• Fanskya (mozafancogene autotemcel)

Snippet

Status: Application withdrawn. Therapeutic area: Fanconi Anemia. MAH: Rocket Pharmaceuticals B.V.. Orphan medicine